Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial

Background and Purpose— In heart failure (HF), left ventricular ejection fraction (LVEF) is inversely associated with mortality and cardiovascular outcomes. Its relationship with stroke is controversial, as is the effect of antithrombotic treatment. We studied the relationship of LVEF with stroke and cardiovascular events in patients with HF and the effect of different antithrombotic treatments. Methods— In the Warfarin Versus Aspirin in Reduced Ejection Fraction (WARCEF) trial, 2305 patients with systolic HF (LVEF⩽35%) and sinus rhythm were randomized to warfarin or aspirin and followed for 3.5±1.8 years. Although no differences between treatments were observed on primary outcome (death, stroke, or intracerebral hemorrhage), warfarin decreased the stroke risk. The present report compares the incidence of stroke and cardiovascular events across different LVEF and treatment subgroups. Results— Baseline LVEF was inversely and linearly associated with primary outcome, mortality and its components (sudden and cardiovascular death), and HF hospitalization, but not myocardial infarction. A relationship with stroke was only observed for LVEF of <15% (incidence rates: 2.04 versus 0.95/100 patient-years; P=0.009), which more than doubled the adjusted stroke risk (adjusted hazard ratio, 2.125; 95% CI, 1.182–3.818; P=0.012). In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1.346; 95% CI, 1.044–1.737; P=0.022; P value for interaction=0.04). Conclusions— In patients with systolic HF and sinus rhythm, LVEF is inversely associated with death and its components, whereas an association with stroke exists for very low LVEF values. An interaction with warfarin treatment on stroke risk may exist. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938.

[1]  M. Domanski,et al.  Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. , 1997, Journal of the American College of Cardiology.

[2]  George A. Johnson,et al.  Risk of Thromboembolism in Heart Failure: An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2007, Circulation.

[3]  J. Feinglass,et al.  Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. , 1997, American heart journal.

[4]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[5]  G. Lamas,et al.  Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. , 1997, Circulation.

[6]  P. Challande,et al.  Opposite Predictive Value of Pulse Pressure and Aortic Pulse Wave Velocity on Heart Failure With Reduced Left Ventricular Ejection Fraction: Insights From an Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Substudy , 2014, Hypertension.

[7]  Robert R. Edelman,et al.  Fat‐Suppressed Breath‐Hold Magnetic Resonance Coronary Angiography , 1993, Circulation.

[8]  K. Swedberg,et al.  Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. , 2013, American heart journal.

[9]  J. Cohn,et al.  Incidence of Thromboembolic Events in Congestive Heart Failure , 1993, Circulation.

[10]  T. LeJemtel,et al.  Low incidence of stroke in ambulatory patients with heart failure: a prospective study. , 1993, American heart journal.

[11]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[12]  D. Kaye,et al.  Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. , 2012, International journal of cardiology.

[13]  S. Solomon,et al.  Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. , 2008, Journal of the American College of Cardiology.

[14]  G. Lip,et al.  Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial , 2013, Circulation. Heart failure.

[15]  Harlan M Krumholz,et al.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.

[16]  S. Solomon,et al.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. , 2012, Journal of the American College of Cardiology.

[17]  V. Fuster,et al.  The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.

[18]  K. Swedberg,et al.  The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND‐HF Trial , 2014, European journal of heart failure.